GSTM1 and chronic kidney disease: Comparative studies of daprodustat versus ESAs (ASCEND-D [Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis] in dialysis patients [7] and ASCEND-ND [Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis] in non-dialysis patients with CKD [8]) showed inferior Hb changes and cardiovascular outcomes with ESAs.